‘Big Shoes To Fill’: US FDA Commissioner Hahn’s Baptism By Fire
Every new FDA commissioner faces a challenge earning credibility with Congress and the public, but in the context of COVID-19, Stephen Hahn has a double challenge of a public health crisis – and the ongoing prominence of his predecessor at the agency.
You may also be interested in...
FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
Final phase overhaul of FDA's new drug review groups includes half-a-dozen first-time division directors. Most have long experience at the agency – but not all with the drugs they will now oversee.